Recent deals include the completed acquisition of efimosfermin, a potential treatment for liver disease, and new partnerships with Hengrui Pharma, aimed at developing up to 12 medicines in ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK plc (LSE/NYSE:GSK) announced Monday the completion of its acquisition of efimosfermin alfa from Boston Pharmaceuticals. The deal includes an upfront payment of $1.2 billion and up to $800 million ...